-+ 0.00%
-+ 0.00%
-+ 0.00%
Journey Medical Q2 revenue rises 23% to $18.5 million on Emrosi sales growth
Share
Listen to the news
Journey Medical Q2 revenue rises 23% to $18.5 million on Emrosi sales growth
  • Fortress Biotech unit Journey Medical posted Q2 2026 revenue of USD 18.5 million, up 23% year over year.
  • Emrosi revenue reached USD 8.1 million; total prescriptions rose to about 36,000 from about 30,000 in Q1 2026.
  • GAAP net loss narrowed to USD 312,000 from USD 3.8 million a year earlier; gross margin held at 67%.
  • Cash and cash equivalents totaled USD 25.6 million at June 30, 2026, up from USD 24.1 million at year-end 2025.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fortress Biotech Inc. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending